Neovasc Inc (NASDAQ: NVCN) is having an incredibly strong start to the trading session this morning, and for good reaosn. The company announced that its Tiara™ transcatheter mitral valve replacement device was featured in a “Live Case” broadcast. Of course, the news excited investors, sending the stock on a run for the top. Today, we’ll talk about:
- The live case broadcast;
- what we’re seeing from NVCN as a result;
- and what we’ll be watching for haead.
NVCN Heads For The Top On Live Case Broadcast
As mentioned above, Neovasc is having an incredibly strong start to the trading session this monring after announcing that its Tiara™ transcatheter mitral valve replacement device was featured in a live case broadcast. The broadcast was provided at the 11th Annual Transcatheter Valve Therapy Conference (TVT 2018).
In the release, NVCN said that at the conference, Dr. Anson Cheung, and Dr. John G. Webb of St. Paul’s Hospital successfully implanted a 40mm Tiara transcatheter valve in a patient suffering from severe mitral regurgitation. Following the case, Dr. Anson Cheung had these comments to offer:
This patient suffered from severe mitral regurgitation and a number of co-morbidities which made him a very poor candidate for surgery. The Heart Team weighed in on all available treatment options and determined the Tiara device was the best option for this patient. The Tiara case was very straight-forward, with an implant time of under 20 minutes, with no procedural complications. Following the Tiara implant the patient’s mitral regurgitation was completely resolved, with a 1mmHg gradient and no paravalvular leak. The patient is recovering well at this time.
The above statement was followed up by Fred Colen, President and CEO at NVCN. Here’s what he had to offer:
This live case broadcast reinforced Tiara’s potential as a promising treatment option for patients who are not suitable for open-heart surgical valve replacement… Attending physicians were able to see first-hand the simplicity of the minimally invasive, transapical transcatheter approach and resulting complete elimination of the patient’s MR. We look forward to continuing to expand our Tiara clinical program and ultimately the adoption of Tiara for routine use in these patients once regulatory approvals are obtained.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to dig into the market is that the news causes moves. With the live case broadcast acting as yet another source of validation for the Tiera, it only makes sense that excited investors are sending Neovasc toward the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:45), NVCN is trading at $0.044 per share after a gain of $0.006 per hsare or 15.62% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
Waht We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NVCN. In particular, we’re interested in following the story surrounding the company’s continued work with regard to the Tiera. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!